#Internacional | Daiichi Sankyo presentará los avances y resultados de sus anticuerpos conjugados en el Simposio de #CáncerDeMama de San Antonio consalud.es/ecsalud/intern…

FDA approves Alzheimer’s drug lecanemab amid safety concerns go.nature.com/3XeheL9

Enhorabuena a nuestro egresado Jesús Ángel Martín Illán, PhD por su tesis doctoral

Besos, abrazos, caricias… son importantes hoy y todos los días. Y más para las personas con #cáncer. En #DaiichiSankyo trabajamos con pasión por la #innovación y compromiso con los #pacientes. Lo hacemos con el 💙 -o con Ishokenmei 🇯🇵 , que muy nuestro, lo decimos alto y claro👇

Pfizer’s acquisition of Seagen will have an impact on drug development in UC. EV/pembro’s potential move into the 1st line is the most important step in advanced disease. DV is perhaps the most exciting early phase agent. pfizer.com/news/press-rel…

Presenting our RWD case series describing activity of TDXd in heavily pretreated HER2+ Leptomeningeal Metastases. Formal neuroradiology MRI reads by EORTC/RANO-LM Revised-Scorecard ORR 50%, CBR 100% #bcsm ⁦Dana-Farber’s Breast Oncology Center⁩ ⁦Duke Center for Brain and Spine Metastasis⁩ ⁦ nature.com/articles/s4152…

101 citations 💪🏼💪🏼 #COFs scholar.google.es/citations?user…

Good news! our Jesús Ángel Martín Illán, PhD NanoUp - Maspoch Group article Macroscopic Ultralight Aerogel Monoliths of Imine-based Covalent Organic Frameworks doi.org/10.1002/anie.2… received enough downloads to be a #topdownloadedarticle in Angewandte Chemie.

Among the most thought-provoking posters of #AACR23: Revisiting the Dogma of ADCs, by @Raffaele_1985 & colleagues. Many important insights on the mechanism of action and toxicity of ADCs.

Impressive waterfall plots for SHR-A1811 in HER2+ and HER2-low MBC. Responses observed at all dose levels and in patients receiving prior HER2 ADCs. #AACR23

Evolution of covalent organic frameworks: From design to real-world applications sciencedirect.com/science/articl…

After being announced to be positive, the TROPION-Breast01 phase 3 trial officially joins the already stellar list of abstracts planned to be presented at #ESMO23! #bcsm ESMO - Eur. Oncology

Quite encouraging activity (ORR 30%) of T-DXd across ERBB2-mutant tumors (#DPT01)- yet interesting to see even more enhanced activity in #DPT02 (IHC 2+/3+), for which we’ll see survival data at #ESMO23. ILD remains a key side effect to remember and proactively manage (#5Srules)

Finding the positive in the TNBC #ESMO2023 #breastcancer Eva M Ciruelos

Dra. Virginia Martínez : ¿Y si resulta que con los nuevos ADCs en CMA, no necesitamos saber el estado de ESR1 o PI3K? #7NovMamaCentro

La Alianza #DaiichiSankyoES | AstraZeneca España se ha unido hoy a la #MareaRosa de #Madrid para seguir visibilizando el #CáncerDeMamaMetastásico a través de #laMquefalta. Por ellas. Asociación Española Cáncer de Mama Metastásico ¿Te sumas? 👉 onconecta2.com/campanas/laMqu…

Thanks to Jesus Jesús Ángel Martín Illán, PhD, Ana and Laura, great work!! Also to our outstanding col. Pilar Ocon and Daniel Maspoch NanoUp - Maspoch Group a privilege to colaborate with both. IFIMAC - Condensed Matter Physics Center UAM Autónoma Madrid Facultad de Ciencias onlinelibrary.wiley.com/doi/10.1002/ad…